An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome (Q37689166)

22 August 2017

1 reference

title

An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

22 August 2017

0 references

0 references

1 reference

1 reference

1 reference

Dorte Glintborg

1

0 references

Marianne Andersen

object named as

Marianne Andersen

series ordinal

2

0 references

publication date

1 April 2010

1 reference

Gynecological Endocrinology

22 August 2017

1 reference

22 August 2017

26

1 reference

22 August 2017

4

1 reference

22 August 2017

281-296

1 reference

A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Hypersecretion of luteinizing hormone and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The android woman--a risky condition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The prevalence of eating disorders in women with facial hirsutism: an epidemiological cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Cytokines and steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Pathophysiology and types of dyslipidemia in PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Bone effects of glitazones and other anti-diabetic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Looking for polycystic ovary syndrome genes: rational and best strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Polycystic ovary syndrome and its developmental origins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Fetal plasma testosterone correlates positively with cortisol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Prevalence of polycystic ovary syndrome in women from opposite-sex twin pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590903247873

10.3109/09513590903247873

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20141388